By Mike Duncan | April 2026
Most institutional allocators believe they are buying factor exposure when they invest in QIS.
They are also buying a set of structural dependencies that the marketing presentation never addresses.
QIS is not just a strategy. It is a structure: a bilateral OTC contract with a dealer who prices your position, provides your liquidity, and controls your exit. The factor exposure is real. The structural dependency is equally real and far less examined.
Most allocator analysis stops at the signal layer. Does the factor work? Is the backtest credible? Is the Sharpe ratio attractive? These are the right questions for the first layer. They are the wrong questions for the layers where outcomes are actually determined: execution, funding, counterparty dependency, and what a stressed exit costs when every other investor in the same crowded strategy wants out at the same moment.
Three forces are making this more urgent. More capital is running more similar signals than at any prior point in the product’s history. Dealer capacity to intermediate that risk is more constrained and more cyclical than it was before the GFC. Strategy differentiation between providers has narrowed, increasing the likelihood of synchronised behaviour under stress.
None of this shows up in backtests. All of it defines outcomes in live markets.
This executive brief covers the four structural risks most allocators are not being shown, how crowding can lead to loss through a mechanism backtests cannot model, and five questions every investment committee should have clear answers to before committing capital.
Read the Executive Brief
Quantitative Investment Strategies – What the Signal Doesn’t Show You
